Long‐term exposure to monoclonal anti‐TNF is associated with an increased risk of lymphoma in BAFF‐transgenic mice | Zendy

Nocturne Gaetane | Zendy; Ly Bineta | Zendy; Paoletti Audrey | Zendy; Pascaud Juliette | Zendy; Seror Raphaele | Zendy; Nicco Carole | Zendy; Mackay Fabienne | Zendy; Vincent F.B. | Zendy; Lazure Thierry | Zendy; Ferlicot Sophie | Zendy; Stimmer Lev | Zendy; Pascal Quentin | Zendy; Roulland Sandrine | Zendy; Krzysiek Roman | Zendy; HaceinBey Salima | Zendy; Batteux Frederic | Zendy; Mariette Xavier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long‐term exposure to monoclonal anti‐TNF is associated with an increased risk of lymphoma in BAFF‐transgenic mice

Author(s) -

Nocturne Gaetane,

Ly Bineta,

Paoletti Audrey,

Pascaud Juliette,

Seror Raphaele,

Nicco Carole,

Mackay Fabienne,

Vincent F.B.,

Lazure Thierry,

Ferlicot Sophie,

Stimmer Lev,

Pascal Quentin,

Roulland Sandrine,

Krzysiek Roman,

HaceinBey Salima,

Batteux Frederic,

Mariette Xavier

Publication year - 2021

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13602

Subject(s) - monoclonal antibody , immunology , lymphoma , tumor necrosis factor alpha , autoimmunity , medicine , b cell activating factor , rituximab , spleen , monoclonal , b cell , flow cytometry , antibody

Summary The impact of treatment on the risk of lymphoma in patients with rheumatoid arthritis (RA) is unclear. Here, we aimed to assess if the risk of lymphoma differs according to the type of tumor necrosis factor inhibitor (TNFi), comparing monoclonal anti‐TNF antibodies to the soluble TNF receptor. We used B cell activating factor belonging to the TNF family (BAFF)‐transgenic (Tg) mice as a model of autoimmunity‐associated lymphoma. Six‐month‐old BAFF‐Tg mice were treated with TNFi for 12 months. Histological examination of the spleen, assessment of the cellular composition of the spleen by flow cytometry and assessment of B cell clonality were performed at euthanasia. Crude mortality and incidence of lymphoma were significantly higher in mice treated with monoclonal anti‐TNF antibodies compared to both controls and mice treated with the soluble TNF receptor, even at a high dose. Flow cytometry analysis revealed decreased splenic macrophage infiltration in mice treated with monoclonal anti‐TNF antibodies. Overall, this study demonstrates, for the first time, that a very prolonged treatment with monoclonal anti‐TNF antibodies increase the risk of lymphoma in B cell‐driven autoimmunity. These data suggest a closer monitoring for lymphoma development in patients suffering from B cell‐driven autoimmune disease with long‐term exposure to monoclonal anti‐TNF antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research